Diamyd Medical AB (publ) reported earnings results for the third quarter and nine months ended May 31, 2023. For the third quarter, the company reported sales was SEK 0.148 million compared to SEK 0.374 million a year ago. Revenue was SEK 5.83 million compared to SEK 1.02 million a year ago. Net loss was SEK 20.64 million compared to SEK 17.1 million a year ago. Basic loss per share from continuing operations was SEK 0.3 compared to SEK 0.2 a year ago.
For the nine months, sales was SEK 0.472 million compared to SEK 0.338 million a year ago. Revenue was SEK 8.44 million compared to SEK 1.41 million a year ago. Net loss was SEK 78.56 million compared to SEK 63.41 million a year ago. Basic loss per share from continuing operations was SEK 1 compared to SEK 0.8 a year ago.